Loading...
Carna Biosciences, Inc.
4572.T•JPX
Healthcare
Biotechnology
¥300.00
¥-6.00(-1.96%)
Carna Biosciences, Inc. (4572.T) Financial Performance & Income Statement Overview
Review Carna Biosciences, Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
-60.87%
↓ 60.87%
Operating Income Growth
-85.87%
↓ 85.87%
Net Income Growth
-88.97%
↓ 88.97%
Operating Cash Flow Growth
18.04%
↑ 18.04%
Operating Margin
-359.91%
↓ 359.91%
Gross Margin
71.96%
↑ 71.96%
Net Profit Margin
-380.22%
↓ 380.22%
ROE
-88.49%
↓ 88.49%
ROIC
-106.71%
↓ 106.71%
Carna Biosciences, Inc. (4572.T) Income Statement & Financial Overview
Review Carna Biosciences, Inc.'s (4572.T) income statement with detailed quarterly and annual figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Cash & Cash Equivalents | $1.53B | $2.11B | $2.28B | $3.03B |
| Short Term Investments | $0.00 | $0.00 | $0.00 | $0.00 |
| Cash & Short Term Investments | $1.53B | $2.11B | $2.28B | $3.03B |
| Net Receivables | $83.27M | $87.09M | $76.33M | $98.99M |
| Inventory | $160.85M | $154.15M | $153.53M | $147.48M |
| Other Current Assets | $352.71M | $388.00M | $334.60M | $272.02M |
| Total Current Assets | $2.13B | $2.74B | $2.85B | $3.54B |
| Property Plant & Equipment (Net) | $0.00 | $0.00 | $93.11M | $99.07M |
| Goodwill | $0.00 | $0.00 | $0.00 | $0.00 |
| Intangible Assets | $0.00 | $0.00 | $474000.00 | $679000.00 |
| Goodwill & Intangible Assets | $0.00 | $0.00 | $474000.00 | $679000.00 |
| Long Term Investments | $0.00 | $34.40M | $37.78M | $0.00 |
| Tax Assets | $0.00 | $0.00 | $0.00 | $0.00 |
| Other Non-Current Assets | $46.21M | $1000.00 | $37.78M | $41.38M |
| Total Non-Current Assets | $46.21M | $34.40M | $131.37M | $141.13M |
| Total Assets | $2.17B | $2.77B | $2.98B | $3.69B |
| Account Payables | $0.00 | $2.00M | $0.00 | $0.00 |
| Short Term Debt | $19.99M | $28.10M | $45.003M | $70.002M |
| Tax Payables | $0.00 | $0.00 | $0.00 | $23.64M |
| Deferred Revenue | $0.00 | $1.45M | $0.00 | $0.00 |
| Other Current Liabilities | $130.80M | $191.41M | $197.40M | $277.00M |
| Total Current Liabilities | $150.79M | $222.97M | $242.40M | $370.64M |
| Long Term Debt | $3.41M | $33.24M | $13.41M | $18.41M |
| Deferred Revenue Non-Current | $0.00 | $0.00 | $0.00 | $0.00 |
| Deferred Tax Liabilities Non-Current | $0.00 | $0.00 | $0.00 | $0.00 |
| Other Non-Current Liabilities | $62.19M | $40.56M | $67.31M | $81.28M |
| Total Non-Current Liabilities | $65.60M | $73.80M | $80.72M | $99.69M |
| Capital Lease Obligations | $0.00 | $32.94M | $0.00 | $0.00 |
| Total Liabilities | $216.39M | $296.76M | $323.13M | $470.33M |
| Preferred Stock | $0.00 | $0.00 | $0.00 | $634000.00 |
| Common Stock | $2.45B | $2.45B | $2.26B | $2.26B |
| Retained Earnings | -$6.75B | -$6.25B | -$5.66B | -$5.17B |
| Accumulated Other Comprehensive Income/Loss | $62.61M | $82.92M | $50.08M | $116.00M |
| Total Stockholders Equity | $1.96B | $2.48B | $2.65B | $3.22B |
| Total Equity | $1.96B | $2.48B | $2.65B | $3.22B |
| Total Liabilities & Stockholders Equity | $2.17B | $2.77B | $2.98B | $3.69B |
| Total Investments | $0.00 | $34.40M | $37.78M | $41.38M |
| Total Debt | $23.40M | $61.34M | $58.41M | $88.41M |
| Net Debt | -$1.51B | -$2.05B | -$2.22B | -$2.94B |
Carna Biosciences, Inc. (4572.T) Balance Sheet Analysis
Carna Biosciences, Inc. (4572.T) manages its money wisely, with plenty of 18.04% and -88.97% to cover its bills. The company’s long-term debts are manageable, balanced by steady -380.22%. Shareholders’ stake in the business has shrunk. Overall, the numbers show a cautious position, giving it room to invest, expand, or adapt. For investors, this paints a risky picture for the future.Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan